References
- Van Epps HL. René Dubos: unearthing antibiotics. J Exp Med. 2006;203:259.
- Davies J. Where have all the antibiotics gone? can. J Infect Dis Med Microbiol. 2006;17:287–290.
- Ruiz-Martínez L, López-Jiménez L, d’Ostuni V, et al. A mechanism of carbapenem resistance due to a new insertion element (ISPa133) in Pseudomonas aeruginosa. Int Microbiol. 2011;14:51–58.
- Madec J-Y, Haenni M, Nordmann P, et al. ESBL/AmpC- and carbapenemase-producing Enterobacteriaceae in animals: a threat for humans? Clin Microbiol Infect. 2017 28 Jan 2017. DOI:10.1016/j.cmi.2017.01.013.
- Li Y, Metcalf BJ, Chochua S, et al. Penicillin-binding protein transpeptidase signatures for tracking and predicting β-lactam resistance levels in Streptococcus pneumoniae. MBio. 2016;7:e00756–16.
- Mendelman PM, Caugant DA, Kalaitzoglou G, et al. Genetic diversity of penicillin G-resistant Neisseria meningitidis from Spain. Infect Immun. 1989;57:1025–1029.
- Nikaido H, Pagès J-M. Broad-specificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria. FEMS Microbiol Rev. 2012;36:340–363.
- Algburi A, Comito N, Kashtanov D, et al. Control of biofilm formation: antibiotics and beyond. Appl Environ Microbiol. 2017;83:e02508–16.
- Enright MC, Robinson DA, Randle G, et al. The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA). Proc Natl Acad Sci U S A. 2002;99:7687–7692.
- Springer B, Kidan YG, Prammananan T, et al. Mechanisms of streptomycin resistance: selection of mutations in the 16S rRNA gene conferring resistance. Antimicrob Agents Chemother. 2001;45:2877–2884.
- Humphries RM, Pollett S, Sakoulas G. A current perspective on daptomycin for the clinical microbiologist. Clin Microbiol Rev. 2013;26:759–780.
- O’Neil J. Tackling drug-resistant infections globally: final report and recommendations. Available from: https://amr-review.org/sites/default/files/160525_Final paper_with cover.pdf. [ Last accessed 5 Dec 2016].
- Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the infectious diseases society of America. Clin Infect Dis. 2009;48:1–12.
- EDCD,antimicrobial-resistance-europe-2014. Available from: http://ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-europe-2014.pdf. [ cited 2016 Nov 1]
- Davies J, Davies D. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev. 2010;74:417–433.
- Jenssen H, Hamill P, Hancock REW. Peptide antimicrobial agents. Clin Microbiol Rev. 2006;19:491–511.
- Karaiskos I, Souli M, Galani I, et al. Colistin: still a lifesaver for the 21st century? expert opin. Drug Metab Toxicol. 2016;13:1–13.
- Rios AC, Moutinho CG, Pinto FC, et al. Alternatives to overcoming bacterial resistances: state-of-the-art. Microbiol Res. 2016;191:51–80.
- Kozlowska J, Vermeer LS, Rogers GB, et al. Combined systems approaches reveal highly plastic responses to antimicrobial peptide challenge in Escherichia coli. Plos Pathog. 2014;10:e1004104.
- Brogden KA. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat. Rev Microbiol. 2005;3:238–250.
- Epand RF, Ramamoorthy A, Epand RM. Membrane lipid composition and the interaction of pardaxin: the role of cholesterol. Protein Pept Lett. 2006;13:1–5.
- Hallock KJ, Lee D-K, Ramamoorthy A. MSI-78, an analogue of the magainin antimicrobial peptides, disrupts lipid bilayer structure via positive curvature strain. Biophys J. 2003;84:3052–3060.
- Katherine A, Henzler-Wildman ‡,⊥, Gary V, et al. Perturbation of the hydrophobic core of lipid bilayers by the human antimicrobial peptide LL-37. Biochemistry. 2004;43:8459–8469.
- Teixeira V, Feio MJ, Bastos M. Role of lipids in the interaction of antimicrobial peptides with membranes. Prog Lipid Res. 2012;51:149–177.
- Yeaman MR, Yount NY. Mechanisms of antimicrobial peptide action and resistance. Pharmacol Rev. 2003;55:27–55.
- Hassan M, Kjos M, Nes IF, et al. Natural antimicrobial peptides from bacteria: characteristics and potential applications to fight against antibiotic resistance. J Appl Microbiol. 2012;113:723–736.
- Nguyen LT, Haney EF, Vogel HJ. The expanding scope of antimicrobial peptide structures and their modes of action. Trends Biotechnol. 2011;29:464–472.
- Gruenheid S, Moual H. Resistance to antimicrobial peptides in Gram-negative bacteria. FEMS Microbiol Lett. 2012;330:81–89..
- Francesc R, Cajal Y. Therapeutic potential of antimicrobial peptide. In: Villa TG, Vinas M, editors. New weapons to control bact. Growth Ed: Springer International Publishing; 2016.
- Tang X-J, Thibault P, Boyd RK. Characterisation of the tyrocidine and gramicidin fractions of the tyrothricin complex from Bacillus brevis using liquid chromatography and mass spectrometry. Int J Mass Spectrom Ion Process. 1992;122:153–179.
- Tyrothricin - Drugs.com Available from: https://www.drugs.com/international/tyrothricin.html. [Last accessed 13 Nov 2016].
- Stevenson CL. Advances in peptide pharmaceuticals. Curr Pharm Biotechnol. 2009;10:122–137.
- Boucher HW, Talbot GH, Benjamin DK, et al. 10 x ’20 progress–development of new drugs active against gram-negative bacilli: an update from the infectious diseases society of America. Clin Infect Dis. 2013;56:1685–1694.
- Pastor M, Moreno-Sastre M, Esquisabel A, et al. Sodium colistimethate loaded lipid nanocarriers for the treatment of Pseudomonas aeruginosa infections associated with cystic fibrosis. Int J Pharm. 2014;477:485–494.
- Sans-Serramitjana E, Fusté E, Martínez-Garriga B, et al. Killing effect of nanoencapsulated colistin sulfate on Pseudomonas aeruginosa from cystic fibrosis patients. J Cyst Fibros. 2016;15:611–618.
- Rabanal F, Grau-Campistany A, Vila-Farrés X, et al. A bioinspired peptide scaffold with high antibiotic activity and low in vivo toxicity. Sci Rep. 2015;5:10558.
- Rudilla H, Fusté E, Cajal Y, et al. Synergistic antipseudomonal effects of synthetic peptide AMP38 and carbapenems. Molecules. 2016;21:1223.
- Grau-Campistany A, Pujol M, Marqués AM, et al. Membrane interaction of a new synthetic antimicrobial lipopeptide sp-85 with broad spectrum activity. Colloids Surfaces Physicochem Eng Asp. 2015;480:307–317.
- Grau-Campistany A, Manresa Á, Pujol M, et al. Tryptophan-containing lipopeptide antibiotics derived from polymyxin B with activity against Gram positive and Gram negative bacteria. Biochim Biophys Acta. 2016;1858:333–343.
- Bacitracin. Available from: http://www.drugbank.ca/drugs/DB00626. [Last accessed 8 Nov 2016].
- CUBICIN® webpage. Available from: http://cubicin.com/. [Last accessed 5 Nov 2016].
- Knight-Connoni V, Mascio C, Chesnel L, et al. Discovery and development of surotomycin for the treatment of Clostridium difficile. J Ind Microbiol Biotechnol. 2016;43:195–204.
- Srinivas N, Jetter P, Ueberbacher BJ, et al. Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa. Science. 2010;327:1010–1013.
- Polyphor - POL7080. Available from: http://www.polyphor.com/products/pol7080. [Last accessed 13 Nov 2016]
- Polyphor- Ltd POL7080 - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT02897869. [Last accessed 13 Nov 2016].
- Afacan NJ, Yeung ATY, Pena OM, et al. Therapeutic potential of host defense peptides in antibiotic-resistant infections. Curr Pharm Des. 2012;18:807–819.
- Dipexium Pharmaceuticals (DPRX) [Internet]. [cited 2016 Nov 13]. Available from: http://www.dipexiumpharmaceuticals.com/locilex/overview.
- Cutanea Life Sciences. Available from: http://www.cutanea.com/.[Last accessed 13 Nov 2016].
- Soligenix- SGX942- Oral Mucositis. Available from: http://www.soligenix.com/pipeline/biotherapeutics/sgx942-oral-mucositis/.[Last accessed 13 Nov 2016].
- Kudrimoti M, Curtis A, Azawi S, et al. Dusquetide: A novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study. J Biotechnol. 2016;239:115–125.
- Lytix Biopharma - ltx109. Available from: http://www.lytixbiopharma.com/antibacterials/ltx109/.[Last accessed 5 Nov 2016]
- Karolinska Development :: LL-37. Available from: http://www.karolinskadevelopment.com/en/portfolio/infections-and-wound-healing/ll-37/.[Last Accessed 13 Nov 2016]
- Cellceutix Corporation - Brilacidin. Available from: http://cellceutix.com/brilacidin/#sthash.HimRvENG.dpbs. [Last accessed 22 Nov 2016]
- C3 Jian. Available from: http://www.c3-jian.com/c3-jian-completes-second-phase-2-clinical-trial-of-anti-cavity-drug/.[Last Accessed 5 Nov 2016]
- Guo L, McLean JS, Yang Y, et al. Precision-guided antimicrobial peptide as a targeted modulator of human microbial ecology. Proc Natl Acad Sci U S A. 2015;112:7569–7574.
- Helix BioMedix |Anti-Infective HB1345 Available from: http://www.helixbiomedix.com/antiinfective.html. [Last accessed 13 Nov 2016]
- Adenium Biotech. Available from: http://adeniumbiotech.com/pipeline/. [Last accessed 5 Nov 2016].
- Oragenics, Inc. (OGEN),OG253. Available from: http://www.oragenics.com/technology-pipeline/lantibiotics/og253. [Last accessed 13 Nov 2016]
- Cantab Anti-infectives - Products Overview. Available from: http://www.cantabanti.com/nvb333.html. [Last accessed 6 Nov 2016]
- Ni W, Shao X, Di X, et al. In vitro synergy of polymyxins with other antibiotics for Acinetobacter baumannii: a systematic review and meta-analysis. Int J Antimicrob Agents. 2015;45:8–18..
- Liu B, Liu Y, Di X, et al. Colistin and anti-Gram-positive bacterial agents against Acinetobacter baumannii. Rev Soc Bras Med Trop. 2014;47:451–456.
- Hornsey M, Wareham DW. In vivo efficacy of glycopeptide-colistin combination therapies in a Galleria mellonella model of Acinetobacter baumannii infection. Antimicrob Agents Chemother. 2011;55:3534–3537.
- Yang H, Chen G, Hu L, et al. Enhanced efficacy of imipenem-colistin combination therapy against multiple-drug-resistant Enterobacter cloacae: in vitro activity and a Galleria mellonella model. J Microbiol Immunol Infect. 2016 29 jan 2016. DOI:10.1016/j.jmii.2016.01.003.
- D’Souza BB, Padmaraj SR, Rekha PD, et al. In vitro synergistic activity of colistin and ceftazidime or ciprofloxacin against multidrug-resistant clinical strains of Pseudomonas aeruginosa. Microb Drug Resist. 2014;20:550–554.
- Leu H-S, Ye -J-J, Lee M-H, et al. Synergy of imipenem/colistin methanesulfonate combinations against imipenem-nonsusceptible multidrug-resistant Acinetobacter baumannii. J Microbiol Immunol Infect. 2014;47:406–411.
- Kumar SN, Lankalapalli RS, Kumar BSD. In vitro antibacterial screening of six proline-based cyclic dipeptides in combination with β-lactam antibiotics against medically important bacteria. Appl Biochem Biotechnol. 2014;173:116–128.
- Wang Z, Zhang L, Wang J, et al. Synergistic interaction of PMAP-36 and PRW4 with aminoglycoside antibiotics and their antibacterial mechanism. World J Microbiol Biotechnol. 2014;30:3121–3128.
- Giacometti A, Cirioni O, Kamysz W, et al. In vitro activity of MSI-78 alone and in combination with antibiotics against bacteria responsible for bloodstream infections in neutropenic patients. Int J Antimicrob Agents. 2005;26:235–240.
- Simonetti O, Cirioni O, Ghiselli R, et al. In vitro activity and in vivo animal model efficacy of IB-367 alone and in combination with imipenem and colistin against Gram-negative bacteria. Peptides. 2014;55:17–22.
- Mulet-Powell N, Lacoste-Armynot AM, Viñas M, et al. Interactions between pairs of bacteriocins from lactic bacteria. J Food Prot 1998;61:1210–1212.
- Pletzer D, Hancock REW. Antibiofilm peptides: potential as broad-spectrum agents. J Bacteriol. 2016;198:2572–2578.
- Høiby N, Bjarnsholt T, Givskov M, et al. Antibiotic resistance of bacterial biofilms. Int J Antimicrob Agents. 2010;35:322–332.
- Nuri R, Shprung T, Shai Y. Defensive remodeling: how bacterial surface properties and biofilm formation promote resistance to antimicrobial peptides. Biochim Biophys Acta. 2015;1848:3089–3100.
- Padhi A, Sengupta M, Sengupta S, et al. Antimicrobial peptides and proteins in mycobacterial therapy: current status and future prospects. Tuberculosis. 2014;94:363–373.
- Gutsmann T. Interaction between antimicrobial peptides and mycobacteria. Biochim Biophys Acta. 2016;1858:1034–1043.
- Silva T, Magalhães B, Maia S, et al. Killing of Mycobacterium avium by lactoferricin peptides: improved activity of arginine- and D-amino-acid-containing molecules. Antimicrob Agents Chemother. 2014;58:3461–3467.
- Rivas-Santiago B, Rivas Santiago CE, Castañeda-Delgado JE, et al. Activity of LL-37, CRAMP and antimicrobial peptide-derived compounds E2, E6 and CP26 against Mycobacterium tuberculosis. Int J Antimicrob Agents. 2013;41:143–148.
- Lan Y, Lam JT, Siu GKH, et al. Cationic amphipathic D-enantiomeric antimicrobial peptides with in vitro and ex vivo activity against drug-resistant Mycobacterium tuberculosis. Tuberculosis. 2014;94:678–689.
- Ramón-García S, Mikut R, Ng C, et al. Targeting Mycobacterium tuberculosis and other microbial pathogens using improved synthetic antibacterial peptides. Antimicrob Agents Chemother. 2013;57:2295–2303.
- Rautenbach M, Troskie AM, Vosloo JA. Antifungal peptides: to be or not to be membrane active. Biochimie. 2016;130:132–145.
- NovaBiotics NP213. Available from: http://www.novabiotics.co.uk/pipeline/novexatin-np213. [Last accessed 13 Nov 2016]
- Pacgen- Progress on PAC-113. Available from: http://www.marketwired.com/press-release/pacgen-announces-progress-on-pac-113-license-2151000.htm. Last accessed 13 Nov 2016]
- Qi X, Zhou C, Li P, et al. Novel short antibacterial and antifungal peptides with low cytotoxicity: efficacy and action mechanisms. Biochem Biophys Res Commun. 2010;398(3):594–600.
- Rivas L, Luque-Ortega JR, Andreu D. Amphibian antimicrobial peptides and Protozoa: lessons from parasites. Biochim Biophys Acta Biomembr. 2009;1788:1570–1581.
- Angélique L, Frederik W, Garmi J, et al. The potential use of natural and structural analogues of antimicrobial peptides in the fight against neglected tropical diseases. Molecules. 2015;8:15392–15433.
- Gwadz RW, Kaslow D, Lee JY, et al. Effects of magainins and cecropins on the sporogonic development of malaria parasites in mosquitoes. Infect Immun. 1989;57:2628–2633.
- Boman HG, Wade D, Boman IA, et al. Antibacterial and antimalarial properties of peptides that are cecropin-melittin hybrids. FEBS Lett. 1989;259:103–106.
- Feder R, Nehushtai R, Mor A. Affinity driven molecular transfer from erythrocyte membrane to target cells. Peptides. 2001;22:1683–1690.
- Vale N, Aguiar L, Gomes P. Antimicrobial peptides: A new class of antimalarial drugs? Front. Pharmacol. 2014;5:275.
- Zhou L-J, Xia J, Wei H-X, et al. Risk of drug resistance in Plasmodium falciparum malaria therapy—a systematic review and meta-analysis. Parasitol Res. 2017;116:781–788.
- McGwire BS, Olson L, Tack BF, et al. Killing of African trypanosomes by antimicrobial peptides. J Infect Dis. 2003;188:146–152.
- Harrington JM. Antimicrobial peptide killing of African trypanosomes. Parasite Immunol. 2011;33:461–469.
- Souza ALA, Faria RX, Calabrese KS, et al. Temporizin and temporizin-1 peptides as novel candidates for eliminating Trypanosoma cruzi. Plos One. 2016;11:1–20.
- Lacerda AF, Pelegrini PB, de Oliveira DM, et al. Anti-parasitic peptides from arthropods and their application in drug therapy. Front Microbiol. 2016;7:1–11.
- Torrent M, Pulido D, Rivas L, et al. Antimicrobial peptide action on parasites. Curr Drug Targets. 2012;13:1138–1147.
- Landa A, Jiménez L, Willms K, et al. Antimicrobial peptides (Temporin A and Iseganan IB-367): effect on the cysticerci of Taenia crassiceps. Mol Biochem Parasitol. 2009;164:126–130.
- Robinson MW, Donnelly S, Dalton JP. Helminth defence molecules-immunomodulators designed by parasites! Front. Microbiol. 2013;4:1–4.
- Thivierge K, Cotton S, Schaefer DA, et al. Cathelicidin-like Helminth Defence Molecules (HDMs): absence of cytotoxic, anti-microbial and anti-protozoan activities imply a specific adaptation to immune modulation. Plos Negl Trop Dis. 2013;7:e2307.
- Ageitos JM, Sánchez-Pérez A, Calo-Mata P, et al. Antimicrobial peptides (AMPs): ancient compounds that represent novel weapons in the fight against bacteria. Biochem Pharmacol. 2016. 20 Sep 2016. DOI:10.1016/j.bcp.2016.09.018..
- Duquesne S, Destoumieux-Garzón D, Peduzzi J, et al. Microcins, gene-encoded antibacterial peptides from enterobacteria. Nat Prod Rep. 2007;24:708–734.